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Research has consistently shown that sleep apnea is strongly associated with atrial 
fibrillation, with several lines of evidence demonstrating that this relationship is 
bidirectional and that each condition predisposes to and/or exacerbates the other. Many 
studies have suggested potential pathophysiologic mechanisms underlying this 
relationship, and that sleep apnea and atrial fibrillation share many of the same 
cardiovascular risk factors further implies that multiple pathways are likely involved in 
the mechanistic link between the two. Although the sleep apnea-atrial fibrillation 
relationship is quite established, numerous aspects of this association still require further 
study, such as the role of gender and the potential impact of positive airway pressure 
therapy. A deeper understanding of how these individual factors may be involved in the 
interrelationship between sleep apnea and atrial fibrillation has important clinical 
implications, such as for risk stratification and screening of patients. Thus, this study 
aims to further understand the different aspects and modulating factors of the sleep 
apnea-atrial fibrillation link, focusing on central sleep apnea as less is known about the 






A total of 153 patients, originally seen at the cardiac electrophysiology clinic at 
Beth Israel Deaconess Medical Center and subsequently offered home sleep apnea 
testing, were included in this study. Several databases – home sleep apnea testing results, 
polysomnography reports, electrocardiogram reports and patient management systems – 
were used to obtain a variety of data on sleep pathology, high loop gain status, left 
ventricular ejection fraction and positive airway pressure therapy efficacy and 
compliance. Patients were considered to have central sleep apnea if home testing results 
demonstrated a central apnea-hypopnea index of 5 or greater and/or if the patient was 
documented as having high loop gain on polysomnography. Data were analyzed using the 
Statistical Package for Social Sciences software in order to examine how factors such as 
gender and therapy use may affect the sleep apnea-atrial fibrillation relationship, in a 
patient population with sleep pathology of at least moderate severity. 
 
Results 
Statistical analysis revealed significant sleep disturbances in the central sleep 
apnea patients compared to the non-central sleep apnea patients. Gender was found to be 
significantly associated with central sleep apnea, but not obstructive sleep apnea. When 
postmenopausal (age≥51) women were analyzed, very few patients met the study criteria 
for central sleep apnea, yet the majority were documented as having atrial fibrillation. As 
expected, positive airway pressure therapy was found to be beneficial for all users, but 
the common pattern of declining compliance to therapy was seen as adherence decreased 
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over the course of three months. Of the select central sleep apnea patients who had 
sufficient data available, comparison of positive airway pressure therapy and cardiac data 




Through examining different aspects of the sleep apnea-atrial fibrillation 
relationship, this study found promising evidence showing that gender and positive 
airway pressure therapy play important roles. Further studies, with larger sample sizes, 
need to be conducted in order to fully understand the specific impact of factors such as 
gender, gender and age and positive airway pressure therapy on the risks and outcomes in 
patients with sleep apnea and/or atrial fibrillation, and how these factors may change 
depending on the type of sleep apnea. Finally, these results further highlight the growing 
need for an effective collaborative care model between cardiologists and sleep medicine 
clinicians, as the management of patients with sleep apnea and atrial fibrillation requires 
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 Sleep-disordered breathing (SDB) is a general term describing a number of 
conditions whereby abnormal breathing occurs during sleep. The primary types of SDB 
are obstructive sleep apnea (OSA) and central sleep apnea (CSA), both of which cause 
repetitive partial or complete cessation of breathing during sleep (Mohammadieh et al., 
2017). However, while OSA is characterized by breathing cessations that are 
accompanied by respiratory effort to breathe, CSA presents with a lack of such 
respiratory drive (Malhotra and Owens, 2010). This section includes a discussion of the 
basic physiology of normal breathing, the classification, pathophysiology and diagnosis 
of OSA and CSA, epidemiology and clinical aspects. 
 
Basic Physiology of Breathing 
 
 As the process of respiration is fundamental for normal physiological functioning, 
its regulation is consequently subject to tight control. This control of ventilation is 
conceptualized in terms of a feedback loop, in which information from central and 
peripheral sources are relayed to the respiratory center located in the medulla oblongata 
(Corne and Bshouty, 2005). This brainstem respiratory center, which consists of a 
network of neurons known as the pre-Bötzinger complex, then integrates feedback 
information to modify the breathing rhythm output and maintain homeostasis. Generally, 
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feedback to the respiratory center includes chemical, mechanical, and behavioral inputs 
(Chourpiliadis and Bhardwaj, 2020). 
 The chemical and metabolic influences on ventilation are mediated through 
central and peripheral chemoreceptors that are sensitive to changes in PaO2 and PaCO2. 
The central chemoreceptors are found in many brainstem regions, whereas the peripheral 
chemoreceptors – the carotid bodies being the most important – are located in the 
bifurcation of each common carotid artery (Iturriaga et al., 2016). These chemoreceptors 
respond to hypoxic and hypercapnic stimuli to modulate ventilation accordingly. On the 
other hand, mechanical influences on ventilation are represented by sensory afferents 
from the chest wall and respiratory muscles (Chourpiliadis and Bhardwaj, 2020). Perhaps 
as an illustration of the intricacies of ventilation regulation, respiratory muscles such as 
the genioglossus – a pharyngeal dilator muscle that maintains patency of the upper 
airway – are activated by both mechanical and chemical stimuli (Pillar et al., 2001); for 
instance, the genioglossus has upregulated activity in the presence of hypoxia (Gauda et 
al., 1991). Lastly, behavioral inputs also represent an arm of feedback to the respiratory 
center. This category includes the changes in ventilation that occur as an individual 
transitions from wakefulness to sleep (Chourpiliadis and Bhardwaj, 2020). As will be 
further discussed, the loss of the wakefulness drive to breathe and subsequent reliance on 
chemical regulation of ventilation in sleep constitutes part of the pathophysiology of CSA 




Classification, Pathophysiology and Diagnosis – Obstructive Sleep Apnea 
 
 In OSA, recurrent collapse of the upper airway during sleep occurs and results in 
reduced airflow, termed hypopnea, or a complete cessation of airflow altogether, termed 
apnea. Respiratory effort is maintained during the hypopneic or apneic event, which can 
be seen on polysomnography (PSG) as the presence of thoracic and abdominal 
movements.  
Pathophysiologically, OSA can be due to any of a number of causes, including 
reduced pharyngeal dilator muscle forces, a susceptible upper airway anatomy, and 
excessive soft palate tissue. Airway obstruction is more likely to occur when an 
individual sleeps in the supine position, as upper airway collapsibility due to gravity 
increases (Arnold et al., 2017). 
A diagnosis of OSA can be made through either PSG or home sleep apnea testing, 
using criteria from the International Classification of Sleep Disorders (ICSD) which 
specifies the presence of OSA if there are symptoms and comorbidities along with five or 
more predominantly obstructive respiratory events per hour or if there are 15 or more 
predominantly obstructive respiratory events per hour in an asymptomatic individual 
(Laratta et al., 2017). Additionally, the severity of OSA can be determined based on the 
apnea-hypopnea index (AHI), defined as the number of apneas and hypopneas per hour 
of total sleep time. Mild OSA is characterized by an AHI of 5 or greater, moderate OSA 




Classification, Pathophysiology and Diagnosis – Central Sleep Apnea 
 
 In CSA, impaired functioning of the medullary respiratory center responsible for 
breathing rhythm generation results in central apneas and hypopneas (Javaheri and 
Dempsey, 2013). In contrast to OSA, no thoracic and abdominal movements are seen on 
PSG. 
 It should be noted that while there is an abundance of pathology-associated cases 
of CSA, CSA can and does occur under normal physiological conditions as well; for 
instance, otherwise healthy individuals may experience sleep transition apneas caused by 
ventilatory instability during the transition from wakefulness to sleep (Malhotra and 
Owens, 2010). For pathologic cases of CSA, classifications are made depending on 
whether the CSA is nonhypercapnic, in which wakefulness PaCO2 levels are normal or 
slightly low, or hypercapnic, in which wakefulness PaCO2 levels are elevated (Eckert et 
al., 2007). The nonhypercapnic group of CSA syndromes includes idiopathic CSA and 
CSA related to medical conditions such as atrial fibrillation (AF), whereas the 
hypercapnic group of CSA syndromes encompasses disorders caused by either an 
impaired central respiratory drive or a downstream impairment in respiratory motor 
control (Eckert et al., 2007). Other pathologic cases of CSA include treatment-emergent 
or treatment-persistent CSA – CSA which arises with use of continuous positive airway 
pressure (CPAP) to treat existing OSA (Malhotra and Owens, 2010). 
As a result of the aforementioned physiological differences between 
nonhypercapnic versus hypercapnic CSA, CSA pathophysiology varies greatly depending 
on the specific CSA syndrome. A general discussion of factors that increase risk of CSA 
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events describes the concepts of apneic threshold (AT) and loop gain (Javaheri and 
Dempsey, 2013, Dempsey et al., 2012). AT refers to a given individual’s critical value of 
PaCO2 for which if the individual’s PaCO2 level falls below this value, then a CSA event 
will occur. Thus, a given individual’s CO2 reserve is highly important as a larger reserve 
– a larger difference between the individual’s eupneic PaCO2 level and AT – will protect 
against CSA events (Muza, 2015). Loop gain refers to the stability of ventilatory control, 
such that high loop gain denotes a system with high instability and low loop gain denotes 
a system with low instability. In a system with high loop gain, then, a given ventilatory 
disturbance results in an over-exaggerated ventilatory response that predisposes the 
individual to breathing instability; an example is the waxing and waning Cheyne-Stokes 
breathing (CSB) pattern – a type of periodic breathing associated with central events – 
experienced by individuals with high chemosensitivity to CO2 levels (Malhotra and 
Owens, 2010).  
A diagnosis of CSA, specifically using PSG (Riha, 2015), can be made when 50% 
or more of total respiratory events are central in nature. Similar to the use of AHI to 
quantify OSA severity, the central apnea-hypopnea index (CAHI) is used to quantify 
CSA severity; a CAHI of 5 or greater is considered abnormal (Muza, 2015). 
 
Epidemiology, Prevalence and Risk Factors 
 
 SDB is commonly seen in the general population, with certain epidemiological 
studies reporting a community prevalence of up to 20% (Jennum and Riha, 2009). For 
OSA in particular, although prevalence estimates vary depending on severity – with 
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estimates of 3-28% for OSA with an AHI≥5 and estimates of 1-14% for OSA with an 
AHI≥15 – it has been reported that 1 in 20 adults experiences OSA with daytime 
impairment (Young et al., 2002). Furthermore, as OSA is a multifactorial disorder with 
many predisposing risk factors including obesity status, gender, age, and hormonal 
factors (Martins et al., 2007), prevalence estimates further vary when these factors are 
taken into account (Young et al., 2002, Garvey et al., 2015). CSA, as compared to OSA, 
has been reported to have a low prevalence at 0.9%, and can also be stratified based on 
factors such as gender and age (Donovan and Kapur, 2016). Current data indicate that 
CSA is commonly seen in older males, with one cohort reporting a prevalence of 7.5% 
for males aged 65 and older (Mehra et al., 2007). Other important risk factors for CSA 
include opioid use and AF in individuals with existing congestive heart failure (CHF) 
(Filiatrault et al., 2016, Sin et al., 1999). 
 
Clinical Aspects – Symptoms and Comorbidities 
 
 In terms of the clinical presentation of SDB, OSA and CSA present in similar 
ways (Malhotra and Owens, 2010). Symptoms of both SDB phenotypes include sleep 
fragmentation, morning headaches, excessive daytime sleepiness (EDS), and more 
(Eckert et al., 2007, Muza, 2015). As the breathing irregularities lead to oxygen 
desaturations and arousals occur, increases in sympathetic nervous system activity ensue 
(Yoshihisa and Takeishi, 2019). This sympathetic activation is thought to contribute to 
the pathogenesis of cardiovascular disease (CVD) (Budhiraja et al., 2010). Therefore, 
major comorbidities associated with SDB include coronary artery disease (CAD), stroke, 
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and AF (Burman, 2017), all of which decrease quality of life and therefore highlight the 
importance of screening for and treating SDB. Figure 1 shows the different pathways 















Clinical Aspects – Treatment 
 
 Treatment of SDB depends on several factors, including disease and symptom 
severity, presence and extent of comorbidities, and patient preferences. Currently, the 
mainstay of SDB treatment is CPAP – a type of positive airway pressure (PAP) in which 
a machine delivers a constant and steady air flow to keep the airways open (Pinto and 
Sharma, 2020), although alternatives such as oral appliances are also available options. 
Importantly, addressing modifiable risk factors, such as weight, through an emphasis on 
lifestyle interventions should not be overlooked as part of SDB treatment (Stephen et al., 
2004). Treatment of CSA in particular, however, is more challenging – options are 
limited and CPAP has failed to show an improvement in survival among patients with 




 AF occurs when disorganized electrical impulses in the atrial chambers of the 
heart lead to an irregular, oftentimes tachycardic, rhythm. As the most common type of 
cardiac arrhythmia, AF represents a significant public health burden (Nesheiwat et al., 
2020). This section includes a discussion of basic heart rhythm physiology and AF 





Basic Cardiac Electrophysiology 
 
 A basic understanding of cardiac electrophysiology is essential for understanding 
the pathophysiology that underlies AF. Normal electrical conduction through the heart 
follows a specific pathway that starts at the sinoatrial (SA) node in the right atrium and 
ends in the many Purkinje fibers that supply the ventricles (Oberman and Bhardwaj, 
2020). Of critical importance to maintaining a normal heart rhythm is the atrioventricular 
(AV) node, downstream of the SA node and located in the right atrium proximal to the 
interatrial septum, which ensures that ventricular contraction occurs following atrial 
contraction (Oberman and Bhardwaj, 2020). To achieve this, conduction is slow through 
the AV node and thus allows for proper ventricular filling with blood and maintenance of 
cardiac output. 
 The electrocardiogram (ECG) reflects the electrical activity of the heart by way of 
electrodes placed on the body surface that measure voltages generated by the different 
regions of the myocardium (Sattar and Chhabra, 2020). Used as a tool for diagnosis of 
CVD, including AF, ECG has major clinical significance. As illustrated in Figure 2, an 
ECG consists of waves, intervals, and segments, with the various terminology – P wave, 
PR interval, QRS complex, T wave, and QT interval – referring to depolarizations and 
repolarizations of specific parts of the heart. Briefly, the P wave represents atrial 
depolarization, the PR interval represents time from first atrial depolarization to first 
ventricular depolarization, the QRS complex – consisting of the Q, R and S waves – 
represents ventricular depolarization, the T wave represents ventricular repolarization, 
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Figure 2: Normal ECG with waves, intervals and segments labeled. Figure from 
Noble et al., 1990. 
 
 
Pathophysiology of Atrial Fibrillation 
 
 In AF, the normal sinus rhythm (SR) – the rhythm which originates from the SA 
node – is instead replaced by rapid and irregular atrial depolarizations, leading to 
uncontrolled electrical activity that cause the atria to quiver, or fibrillate (Dang et al., 
2002). Mechanistically, AF pathogenesis has been described to occur through the 
processes of initiation, brought about by triggers, and perpetuation, brought about by a 
vulnerable atrial substrate (Staerk et al., 2017). AF initiation is described to be caused by 
triggers such as pulmonary vein (PV) ectopic activities. In fact, PV cardiomyocytes have 
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been found to have electrophysiological properties that increase their likelihood of 
causing arrhythmia (Ehrlich et al., 2003). AF perpetuation mechanisms have not yet been 
fully elucidated (Cheniti et al., 2018), but a vulnerable atrial substrate characterized by 
fibrosis and electrical remodeling is thought to promote AF perpetuation. Additional 
modulating factors, such as inflammation, have been found to be associated with AF 
pathogenesis (Phillips, 2013). 
 On ECG, classic features indicating AF include the absence of well-defined P 
waves – reflecting the lack of organized atrial depolarizations – and irregularly irregular 
R-R intervals – reflecting the lack of a pattern of ventricular contraction (Dang et al., 
2002). These hallmark features are illustrated in Figure 3, which shows an ECG tracing 
of an individual with AF. 
 
 
Figure 3: ECG tracing showing AF. Figure from Becker, 2006. 
 
Classification and Diagnosis 
 
 AF is typically classified into three major types – paroxysmal, persistent and 
permanent. Paroxysmal AF is that which lasts less than 48 hours and usually resolves on 
its own; persistent AF is that which lasts for more than a week and continues until an 
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intervention is performed to terminate the arrhythmia; permanent AF is that which 
persists indefinitely despite attempts to restore SR (Dang et al., 2002). 
 AF diagnosis is usually confirmed using ECG when there is a clinical suspicion 
based upon factors such as elevated pulse rate and other symptoms including fatigue, 
palpitations, chest pain, syncope, and more. However, caveats include the fact that ECG 
may not detect a paroxysmal arrhythmia and the fact that patients with AF may be 
asymptomatic. Therefore, additional cardiac monitoring using devices that track activity 
over a 24-hour period or longer may be used in instances where presence of AF is 
inconclusive (Gutierrez and Blanchard, 2016). 
 
Epidemiology, Prevalence and Risk Factors 
 
 AF is a condition on the rise – the 2001 Anticoagulation and Risk Factors in 
Atrial Fibrillation Study predicted a then-estimate of 2.3 million adults in the United 
States with AF and projected this number to increase to upwards of 5.6 million by 2050 
(Go et al., 2001). This increase in AF prevalence reflects the aging population, as age is 
one of the risk factors associated with AF. In fact, AF is reported to be present in just 
0.12%-0.16% of individuals younger than 49 years of age, but in 10%-17% of individuals 
at least 80 years of age. Besides age, sex is also implicated to affect AF occurrence – 
males are 1.2 times more likely than females to have AF (Zoni-Berisso et al., 2014). 
Other important risk factors for AF development include a wide range of conditions and 
lifestyle habits such as sleep apnea, HF, diabetes, hyperthyroidism, obesity, heavy 
alcohol consumption, and more (Brandes et al., 2018). 
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Clinical Aspects – Symptoms and Comorbidities 
 
 Typical AF symptoms include irregular palpitations, shortness of breath, exercise 
intolerance and a general lack of energy. Furthermore, the predominant symptom seen in 
clinic may vary depending on the type of AF (Dang et al., 2002). In terms of 
comorbidities, AF is known to be strongly associated with CVD; however, as previously 
mentioned, non-cardiovascular conditions such as diabetes and SDB have also been 
shown to impact AF development (Ferreira et al., 2015). This study will further examine 
the links between SDB – in particular, CSA – and AF. 
 
Clinical Aspects – Treatment 
 
 As AF is known to confer an increased risk of adverse events – such as stroke, 
transient ischemic attack and even death – it is imperative that AF is properly managed 
(Amin et al., 2016). Generally, AF management is approached as acute treatment and 
long-term treatment. For AF which presents acutely, cardioversion to SR is usually an 
option and the probability of remission is greater than for chronic AF. For chronic AF, 
goals of treatment include symptom and rate control (Kakar et al., 2007). 
 
The Relationship Between Sleep-Disordered Breathing and Atrial Fibrillation 
 
 SDB and AF are both major clinical entities, but the interrelationship between 
them is just as significant. As previously discussed, SDB and AF are commonly 
comorbid, and the presence of one condition is known to increase the risk of developing 
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or exacerbating the other condition. Thus, SDB and AF are putatively linked through a 
bidirectional relationship (Marulanda-Londoño and Chaturvedi, 2017, Leung et al., 
2005). This section will discuss what is known about the relationships between OSA & 
AF and CSA & AF, with a focus on the latter. 
 
Obstructive Sleep Apnea and Atrial Fibrillation 
 
 Many studies point to a strong association between OSA and AF. For instance, it 
has been shown that even after accounting for various CVD confounders – such as CAD, 
HF, and hypertrophic cardiomyopathy – the prevalence of AF is still higher if preexisting 
OSA is present (Lavergne et al., 2015). Conversely, research has also shown that OSA 
risk is greater in the presence of AF – one study found that AF patients were twice as 
likely to develop OSA compared to a general cardiology patient group with CVD but no 
concurrent or history of AF (Gami et al., 2004). Finally, studies have also found that 
untreated OSA negatively impacts AF treatment, as patients using CPAP have lower rates 
of AF recurrence (Marulanda-Londoño and Chaturvedi, 2017). 
 
Central Sleep Apnea and Atrial Fibrillation 
 
 While the association between OSA and AF is quite firmly established, the links 
between CSA and AF are less robust. As is the case for OSA and AF, several lines of 
evidence have indicated that the relationship between CSA and AF is also likely 
bidirectional. In a large retrospective study of CHF patients who were evaluated at a 
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sleep center, researchers found that having AF significantly increased the risk of CSA but 
not OSA (Sin et al., 1999). It has also been demonstrated that this link between CSA and 
AF persists even in the absence of underlying CVD. One study found a higher AF risk in 
patients with idiopathic CSA who did not have a history of CHF (Leung et al., 2005). 
 Several studies have concluded that the association between CSA and AF is even 
more pronounced than that between OSA and AF (Tung et al., 2017). This warrants 
deeper investigations into the CSA-AF relationship, as there are still numerous gaps in 
knowledge; researchers have described how there is a paucity of data on the prevalence 
of CSA in patients with AF (Lavergne et al., 2015). For instance, although studies have 
reported that male gender and increasing age are independent risk factors for CSA (Sin et 
al., 1999), less clearly established are more specific details about the potential effects of 
age and gender – for instance, how CSA in individuals with AF is either over- or 
underrepresented across age groups and between males and females. Furthermore, more 
research is needed in the realm of treatments – in particular, in identifying how treatment 
of CSA affects AF and how efficacious this CSA treatment is (Tung et al., 2017). 
Because of the increased mortality and risk of adverse outcomes associated with having 
both conditions, knowledge regarding treatment effects are of major clinical importance. 
Finally, this also raises the question of how improvements can be made in screening for 





A Collaborative Care Model: Sleep Medicine and Cardiology 
 
As SDB and AF are commonly encountered conditions in their respective 
specialties - sleep medicine and cardiology - but also commonly comorbid and known to 
affect each other, it becomes apparent that a collaborative care system between these two 
medical specialties is essential in order to deliver optimal patient care. A collaborative 
care model recognizes the inherent complexities in managing two or more chronic 
conditions that, together, have significant negative impacts on health outcomes, and 
attempts to better facilitate management of such conditions through coordinated 
partnership. Such collaboration in healthcare not only improves individual and 
community health outcomes, but has also been shown to be cost-effective (Ivbijaro et al., 
2014). 
Numerous examples of successful collaboration have been noted; for instance, 
that between primary care and mental health care (Ivbijaro et al., 2014). Currently, the 
collaboration between sleep medicine and cardiology – especially that relating to sleep 
apnea management – is a work in progress, but one that is clinically important as it 
enhances patient care (Kwon et al., 2018). In this study, the collaboration between sleep 
medicine and cardiology is seen through the referrals and management of patients with 










1) Summarize sleep testing and sleep apnea therapy results, focusing on sleep pathology, 
treatment patterns and treatment outcomes. 
2) Explore the relationship of central sleep apnea or high loop gain effects in atrial 
fibrillation patients. 
3) Assess the impact of gender on the type of sleep apnea and treatment outcomes. 









Study Design and Subjects 
 
This is a retrospective analysis of clinical patient data from home sleep apnea 
testing, PAP therapy and cardiac reports. Subjects are cardiology patients who were seen 
in the cardiac electrophysiology clinic at Beth Israel Deaconess Medical Center (Boston, 
Massachusetts, USA) for cardiac arrhythmia – predominately AF – management, and 
subsequently offered the WatchPAT home sleep apnea testing device.  
WatchPAT sleep study reports were collected for a total of 153 patients; these 
reports contain data collected between 2018 and 2020. Parameters examined in the 
reports – including respiratory indices, oxygen saturation and sleep phases – are used to 
understand how much sleep pathology is present in the study population. Additionally, 
information from these reports are used to explore relationships between SDB, AF and 
gender. 
PAP therapy compliance and efficacy data were available for only 28 patients. 
Many patients had different data available (three-month data only or three- and six-month 
data); however, these data were collected largely between 2018 and 2019, with some 
patients whose therapy is currently ongoing and thus these patients have data in 2020. 
These therapy data are used to understand treatment efficacy outcomes, patterns of 
adherence to therapy over time and any potential effects on cardiac status later on through 







 The WatchPAT device (Itamar Medical, Ltd) was used to screen patients for 
SDB. WatchPAT is a home sleep apnea testing device, approved by the Food and Drug 
Administration (FDA), that is used to detect SDB – both OSA and CSA. The portable 
device is worn on the wrist and uses peripheral arterial tonometry (PAT), pulse oximetry, 
and actigraphy to generate information regarding respiratory disturbances; this allows the 
WatchPAT device to indirectly detect apnea and hypopnea events through measuring the 
changes in peripheral arterial volume using finger plethysmography (Yalamanchali et al., 
2013). Then, this information is analyzed by an automated algorithm, and the results are 
available in a sleep study report. 
 There are many advantages to using the WatchPAT device – the technology is 
portable, non-invasive and accurate. The portability and user-friendliness of WatchPAT 
makes the device a valuable alternative to PSG, which is logistically more difficult for 
patients as testing is performed in a laboratory setting and waiting times to have testing 
done can oftentimes be long (Yalamanchali et al., 2013). However, WatchPAT has 
nevertheless been shown to provide accurate and reliable results, with an abundance of 
studies showing that sleep indices – for instance, AHI – measured using PAT are similar 
to those measured using PSG (Bar et al., 2003, Penzel et al., 2002, Ayas et al., 2003). 
Furthermore, the algorithm used to generate results may be seen as superior to the 






Reports and Databases 
 
 Each WatchPAT sleep study report contains a wide range of information and 
graphical displays – patient characteristics such as body mass index (BMI) and Epworth 
Sleepiness Scale (ESS) score, medical history, concurrent medications, respiratory 
indices, oxygen saturation statistics, pulse rate statistics, sleep stage percentages, and 
more. In addition to the WatchPAT sleep study report generated for each patient, 
compliance and efficacy data from use of different PAP therapy devices were also 
utilized – those from the AirView and Encore databases. AirView and Encore are patient 
management systems used to monitor therapy compliance. AirView and Encore reports 
contain information regarding patient compliance and therapy efficacy and can be 
customized to generate data of a desired timeframe. For this study, three- and six-month 
compliance data were utilized; parameters describe device usage, mask leak and 
respiratory indices. Of note, a substantial number of patients did not have compliance and 
efficacy data available in either of the AirView or Encore databases. Finally, the online 
medical record (OMR) was used to obtain high loop gain data from PSG reports and 




 Data from each patient’s WatchPAT sleep study report, PAP therapy reports from 
AirView and Encore and OMR reports, the latter two if applicable, were entered into 
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Excel and subsequently analyzed using Statistical Package for Social Sciences (SPSS) 
(IBM Corporation, USA). 
 Crosstabulation tables were frequently utilized in order to understand any 
potential association between two categorical variables. Significance values (two-tailed 
p-values) were obtained from the chi-square and Fisher’s exact tests; the latter was 
preferably used whenever a 2x2 contingency table was to be analyzed, since the sample 
sizes were often small. Additionally, two-tailed p-values were also obtained from 
independent samples t-tests that were performed to compare means. For these tests, the 
significance value for Levene’s test for equality of variances was checked; if significance 
was <0.05, then the two-tailed p-value corresponding to “equal variances not assumed” 
was used. Finally, descriptive statistics on frequencies were obtained for categorical 
variables, in order to understand prevalence, and also for scale variables, in order to 






Patient Characteristics and Sleep Pathology 
 
Of the 153 patients, 111 were male and 42 were female. The mean and median 
age of patients were 63.4 and 63 years, respectively. 94 patients had an ESS score and 
150 patients had a BMI reported on their WatchPAT sleep study report; the mean and 
standard deviation for these parameters were 6.14±4.52 for ESS and 29.87±5.65 for BMI. 
When analyzed by gender, the mean and standard deviation for ESS in males and females 
were 5.90±4.47 and 7.04±4.70, respectively. The mean and standard deviation for BMI in 
males and females were 30.30±4.96 and 29.25±6.49, respectively. 
Included in each WatchPAT sleep study report are sections detailing the patient’s 
medical history and current medications. CVD, for instance, is pertinent to a discussion 
of SDB and AF as it is oftentimes a comorbidity shared by both. These clinical data on 
patient comorbidities and medications are summarized in Tables 1 and 2. As shown in 
Table 1, of the arrhythmias, AF was most commonly reported (72.5%). Other frequently 
reported conditions include hypertension (40.5%), hyperlipidemia (17.6%) and thyroid 
diseases such as hyperthyroidism (9.8%); these conditions are indeed all known to be 
associated with either CVD, which predisposes to AF, or AF itself (Ogunsua et al., 2015, 
N and Francis, 2005, Nelson, 2013). Table 2 captures the wide range of medications 
taken by the patients in this study; again, the most commonly used medications were 
those that treat arrhythmias and/or CVD, such as anticoagulants (63.4%), beta-blockers 
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(50.3%), lipid-lowering therapies (39.2%), antiarrhythmics (25.5%), ACE inhibitors 
(22.9%) and antiplatelets (20.9%). 
Table 1. Frequency table of patient comorbidities. 
CAD: coronary artery disease, AF: atrial fibrillation, SVT: supraventricular tachycardia, 








Atrial flutter 9.2 
SVT 3.3 
Ventricular tachycardia 0.7 
Atrial tachycardia 2.6 







Thyroid disease 9.8 
Cancer 5.2 






Carotid stenosis 1.3 




Table 2. Frequency table of patient medications. 
ACE inhibitor: angiotensin-converting enzyme inhibitor, PPI: proton-pump inhibitor, 
ARB: angiotensin receptor blocker, NSAID: nonsteroidal anti-inflammatory drug, H2 
blocker: histamine type 2 receptor blocker, PDE5 inhibitor: phosphodiesterase type 5 




ACE inhibitor 22.9 
Beta-blocker 50.3 
Lipid-lowering therapy 39.2 








Thyroid medicine 11.8 











H2 blocker 2.6 
Digoxin 2.6 
Alpha-adrenergic blocker 3.9 







Table 3 shows the means and standard deviations for the three respiratory indices 
recorded by WatchPAT – AHI, respiratory disturbance index (RDI) and CAHI. The RDI 
is similar to the AHI, but takes into account respiratory effort-related arousals (RERAS) 
in addition to apneas and hypopneas (Krakow et al., 2014). RERAS are defined as 
breathing events, neither classified as apneas nor hypopneas, that are characterized by a 
reduced flow of air due to an obstructed upper airway and that ultimately lead to arousal 
(Tsara et al., 2009). As seen in Table 3, the patients in this study population represent, on 
average, OSA of at least moderate severity (mean AHI of 15.45 and mean RDI of 19.20). 
It should be noted that a considerable number of patients had a CAHI of 0 (n=77); these 
individuals account for almost two-thirds of all patients with a CAHI<5 (n=127). For 
those patients with a CAHI≥5 (n=22), the mean and standard deviation for CAHI were 
14.05 and 9.29, respectively. Thus, the overall patient population may not, on average, 
present with CSA based on CAHI criteria (mean CAHI of 2.60), but for those 22 patients 
with a CAHI≥5, the CSA is, on average, of at least moderate severity. These respiratory 
indices thus demonstrate that the patients in this study represent a group with at least 









Table 3. WatchPAT respiratory index data.  
Values are reported as mean±SD. AHI: apnea-hypopnea index, RDI: respiratory 
disturbance index, CAHI: central apnea-hypopnea index. 
 






Patients with high loop gain were also defined as having CSA; thus, patients were 
classified as having CSA if they had a CAHI≥5 and/or high loop gain present on PSG. 
Patients were classified as not having CSA only if they had a CAHI<5 and had no high 
loop gain present on PSG. A total of 14 patients in this study were recorded as having 
high loop gain. 
 Table 4 summarizes the remaining quantitative parameters measured by 
WatchPAT, with the results categorized by presence or absence of CSA based on the 
aforementioned criteria. Four patients with missing data, either for CAHI or high loop 
gain or both, were excluded from this analysis. The means and standard deviations for all 
parameters reported in Table 4 are quite similar between all patients and patients with a 
CAHI<5 and no high loop gain. However, statistically significant differences were found 
between patients with CAHI<5 and no high loop gain and patients with CAHI≥5 and/or 
high loop gain for two parameters: percentage of deep sleep and oxygen desaturation 
index (ODI). The most pronounced differences shown in Table 4 are thus between 
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patients without CSA and patients with CSA. For these CSA patients, then, the sleep 
pathology is such that sleep architecture and oxygen saturation are significantly affected. 
The results of deep sleep in particular will be further discussed in a subsequent section. 
 
Table 4. Summary of quantitative WatchPAT data. Values are reported as mean±SD. 
Two-tailed p-values are calculated using the independent samples t-test (test variables are 
each of the nine quantitative parameters examined, grouping variable is the presence or 
absence of CSA: CAHI<5 and no HLG and CAHI≥5 and/or HLG). Statistically 
significant p-values (<0.05) are in bold. A confidence interval (CI) of 95% was used. 
HLG: high loop gain, TST: total sleep time, SE: sleep efficiency, REM sleep: rapid eye 
movement sleep, ODI: oxygen desaturation index, SpO2: oxygen saturation, HR: heart 
rate. 
 














 409.45±72.21 410.35±65.99 402.58±82.81 0.565 
SE (%) 
 83.95±7.53 84.23±6.29 82.39±10.55 0.327 
Light sleep 
(%) 66.71±10.45 66.11±10.24 68.39±11.41 0.270 
Deep sleep 
(%) 13.65±5.94 14.33±5.81 11.53±6.19 0.016 
REM sleep 
(%) 19.64±7.26 19.56±7.09 20.08±8.10 0.715 
ODI 
 12.83±13.58 8.25±8.53 26.76±16.36 0.000 
Mean SpO2 
 94.01±1.46 94.14±1.52 93.61±1.20 0.058 
Time (min) 
SpO2<88% 
6.35±18.06 4.73±16.00 12.04±23.47 0.088 
Mean HR 






Central Sleep Apnea-Atrial Fibrillation Interface and Gender Effects 
 
 Based on the medical history provided in the WatchPAT sleep study reports, 111 
patients were documented as having AF. To explore the relationship between preexisting 
AF and CSA risk, a crosstabulation table was generated using presence or absence of AF 
and presence or absence of a CAHI≥5 and/or high loop gain as categorical variables. The 
results, shown in Table 5, show that CSA was considered to be present in 6 out of 22 
patients with no preexisting AF and 23 out of 109 patients with preexisting AF. While the 
table shows a greater absolute number of patients deemed as having CSA in the group of 
patients with AF, statistical analysis using Fisher’s exact test generated a two-tailed p-
value of 0.576. Therefore, in the study population examined, no significant relationship 
was found between CSA and AF. 
 
Table 5. Crosstabulation table for relationship between AF and CSA. 
 
Atrial Fibrillation * CAHI≥5 and/or HLG 
Crosstabulation 




Total No Yes 
Atrial 
Fibrillation 
Absent 16 6 22 
Present 86 23 109 
Total 102 29 131 
 
In order to better understand the impact of gender on the type of SDB (OSA or 
CSA), a crosstabulation table showing the relationship between gender and OSA 
frequency was generated and compared to a crosstabulation table showing the 
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relationship between gender and CSA frequency. Presence or absence of OSA was 
determined based on AHI score; patients were considered to have OSA if their AHI was 
5 or greater. These results, shown in Tables 6 and 7, demonstrate a statistically significant 
relationship between gender and CSA (chi-square two-tailed p-value of 0.027), but not 
between gender and OSA (chi-square two-tailed p-value of 0.203). Both OSA and CSA, 
however, appear to be more prevalent in males than in females. 
 
Table 6. Crosstabulation table for relationship between gender and OSA frequency. 




Total AHI<5 AHI≥5 
Gender Male 32 76 108 
Female 17 25 42 
Total 49 101 150 
 
Table 7. Crosstabulation table for relationship between gender and CSA frequency. 
 






Total No Yes 
Gender Male 75 31 106 
Female 37 5 42 




The vast majority of female patients were 51 years of age or older (40 out of 42); 
these patients were identified in order to examine, as a sub-analysis, the effect of 
postmenopausal status on CSA risk. This age cutoff was based on literature that reports 
the median age of menopause to be 51 years of age (Peacock and Ketvertis, 2020). 
Table 8 shows the results of postmenopausal status on CSA risk in females. These 
results show that postmenopausal females (females ≥51 years of age ) do not seem to be 
at an increased risk for CSA compared to premenopausal females (females <51 years of 
age). Importantly, however, there are significantly fewer females <51 years of age; 
nevertheless, that only 5 out of 40 postmenopausal females had a CAHI≥5 and/or high 
loop gain suggests that postmenopausal status may not play a major role in conferring an 
increased risk of CSA. 
Table 9 shows that although the majority of postmenopausal females did not have 
a CAHI≥5 and/or high loop gain (n=35), the majority, 27 out of 30 patients, were still 
documented to have AF. Five patients were excluded due to missing AF data. Since AF is 
generally thought to be associated with CSA, there may be other factors influencing CSA 
























Table 8. Crosstabulation table for relationship between menopausal status and CSA 
frequency. 
 





CAHI≥5 and/or HLG 
Total No Yes 
Gender Female <51 2 0 2 
≥51 35 5 40 
Total 37 5 42 
Missing AF data 
(n=5) No AF (n=3) AF (n=27) 
Females (n=42) 
Postmenopausal 
(≥51 years) (n=40) 
Premenopausal 
(<51 years) (n=2) 




Table 9. Frequency table displaying prevalence of AF in postmenopausal females 
without CSA (n=35). 
 
Atrial Fibrillation in Postmenopausal Females without CSA 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Absent 3 8.6 10.0 10.0 
Present 27 77.1 90.0 100.0 
Total 30 85.7 100.0  
Missing System 5 14.3   
Total 35 100.0   
 
Positive Airway Pressure Therapy Treatment Outcomes and Attrition 
 
 The compliance and efficacy outcomes of PAP therapy, retrieved from the Encore 
database, are shown in Table 10. The parameters describe device usage, device leak, 
respiratory indices and periodic breathing. The results show that, over a period of three 
months, usage generally declined and leakage increased; but, overall, improvements were 











Table 10. PAP therapy compliance and efficacy data, over three and six months, for 
patients with both three- and six-month data (n=20). Values are reported as 
mean±SD. AHI: apnea-hypopnea index, OA index: obstructive apnea index, CA index: 
central apnea index, PB: periodic breathing. 
 
 3 months 6 months 
Days with device usage 83.25±11.75 159.45±34.03 
Days with usage≥4 hours 
(%) 79.19±21.97 77.12±24.54 
Average usage, days used 
(min) 373.00±80.79 378.85±80.17 
Average usage, all days 
(min) 340.95±102.36 335.85±116.39 
Average time in large leak 
(min) 12.85±32.46 15.05±42.83 
Average % of night in large 
leak 4.23±11.51 4.93±15.03 
Average AHI 3.91±2.97 3.44±2.38 
Average OA index 1.10±1.14 0.94±1.05 
Average CA index 0.60±0.85 0.50±0.74 
Average % of night in PB 2.29±3.25 2.16±3.05 
 
 
On the other hand, Table 11 shows the average residual AHI, average OA index 
and average CA index – each examined over three and six months of therapy use – for 
males and females. As noted in Table 10, all three respiratory indices decreased from 
three to six months of therapy; Table 11 shows that both males and females saw 
decreases in all indices. However, the results demonstrate that gender did not have a 
significant impact on treatment efficacy outcomes in the patient population studied, as all 
p-values were greater than 0.05. 
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Table 11. Three- and six-month average values for respiratory indices in male 
(n=13) versus female (n=7) patients, for patients with both three- and six-month 
data (n=20). Values are reported as mean±SD. Two-tailed p-values are calculated using 
the independent samples t-test (test variables are each of the three respiratory indices 
examined over three and six months, grouping variable is gender: male and female). 
None of the p-values were statistically significant (<0.05). A CI of 95% was used. 
 
 Male (n=13) Female (n=7) P-value 
3 month average 
AHI 3.79±3.05 4.13±3.03 0.817 
6 month average 
AHI 3.29±2.23 3.73±2.79 0.702 
3 month average 
OA index 0.82±0.73 1.63±1.60 0.132 
6 month average 
OA index 0.66±0.55 1.46±1.54 0.229 
3 month average 
CA index 0.49±0.62 0.80±1.19 0.452 
6 month average 
CA index 0.39±0.51 0.70±1.06 0.388 
 
Although PAP therapy data was scarce – available for only 28 patients and only 
20 patients had both three- and six-month compliance data available on Encore – the 
available data show a pattern of attrition. Analysis of compliance data showed that, from 
three to six months, adherence to therapy slightly decreased (Table 10). Over the course 
of three months, the “days with device usage” parameter decreased from a mean of 
91.2% to a mean of 87.4% (three- and six-month mean days with device usage were 
83.25 and 159.45 days, respectively). The “percentage of days where usage was ≥4 hours 
per night” parameter also decreased from a mean of 79.2% to a mean of 77.1%, again, 







 To assess the potential impact of PAP therapy for SDB on cardiac status, left 
ventricular ejection fraction (LVEF) data from patient ECG reports were obtained from 
the OMR. LVEF data was available for 75 patients; for these patients, the mean, standard 
deviation, minimum and maximum LVEF were 56%, 13.33, 10% and 79%, respectively. 
The use of LVEF to reflect cardiac status is based on literature that reports AF patients to 
have adverse hemodynamic changes – specifically, one study found LVEF to 
immediately increase in AF patients after cardioversion to SR (Manning et al., 1994). 
Thus, in this study, improvements in LVEF are used to reflect improvements in AF. 
Focus was on the twelve patients with both LVEF data and three- and six-month 
PAP therapy compliance data. All twelve patients met the criteria for OSA and/or CSA as 
defined in this study: AHI≥5 for OSA and CAHI≥5 and/or high loop gain for CSA. Of 
these twelve patients, six had an ECG report dated after their PAP therapy start date. Of 
these six patients, five had a normal LVEF (>50%) as defined in the literature (Hamdani 
and Paulus, 2011). Each patient’s LVEF percentage was then compared to the 
approximate time elapsed since cardiac data collection and therapy start date, as well as 
their compliance change from three to six months. These comparisons provided the 
context for interpreting cardiac changes that may have been influenced by therapy use. 






Table 12. LVEF data for the six patients with OSA and/or CSA and with three- and 
six-month PAP therapy compliance data. LVEF: Left ventricular ejection fraction. 
Compliance change from three to six months was calculated for each patient using the 
difference between the three- and six-month “Days with Device Usage” percentage 
values. 
 




collection & therapy 
start date 
Compliance change 
from 3 to 6 months 
1 63 1 month 96.4% à 96.4% No change 
2 60 1 year 88.8% à 86.6% -2.2% 
3 55 1 year 98.6% à 99.2% +0.6% 
4 10-15 2 months 70.1% à 63.6% -6.5% 
5 70 4 months 93.2% à 92.6% -0.6% 
6 55 1 year 96.4% à 91.0% -5.4% 
 
 
Epworth Sleepiness Scale and Deep Sleep 
 
For the 94 patients for whom an ESS score was reported on their WatchPAT sleep 
study report, the mean ESS was 6.14 and only 18 patients had an ESS>10. The mean ESS 
for the 28 out of 36 patients with a CAHI≥5 and/or high loop gain for whom a value was 
reported was 5.89. This was not significantly different than the mean ESS for the 48 out 
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of 77 patients with a CAHI of 0 for whom a value was reported, which was 6.63. These 
results suggest that CSA did not seem to significantly impact subjective sleepiness. 
For the 150 patients with available sleep phase percentage data, the mean and 
standard deviation for percentage of deep sleep were 13.65% and 5.94, respectively. Of 
note, a substantial number of patients – 48 out of 150 patients – had <10% deep sleep. 





















Patients and Sleep Pathology 
 
 Analysis of the medical history, concurrent medication and quantitative data from 
each WatchPAT sleep study report shows that the patient population studied has, on 
average, considerable cardiovascular comorbidity and at least moderate severity sleep 
apnea. When the sleep, oxygen saturation and pulse rate parameters were specifically 
examined between patients with CSA and patients without CSA, it was found that those 
with CSA had significantly less deep sleep and a greater ODI. These results are 
consistent with what is known about CSA, and SDB in general – that the repeated lapses 
in breathing not only cause oxygen saturation to decrease, but ultimately lead to arousals 
and less slow-wave, restorative sleep as well (Dempsey et al., 2010). Understanding the 
clinical background and disease severity of patients is important in order to correctly 
interpret the data and draw conclusions from the results. 
 
Central Sleep Apnea, Atrial Fibrillation and Gender 
 
 Although Table 5, which displayed the relationship between patients with 
preexisting AF and CSA frequency, did not show that the association between these two 
variables was statistically significant, the pattern seen in the crosstabulation table still 
showed that those with preexisting AF met the study criteria for CSA more often than 
those without preexisting AF. It is likely that the small sample size of the study, including 
the largely unequal ratio of patients with AF to patients without AF, influenced these 
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results and therefore did not allow for the conclusion of a significant association between 
CSA and AF to be made. 
Upon examining the impact of gender on the type of SDB, the patterns in the 
crosstabulation tables suggested that males generally have a higher frequency of both 
types of SDB – OSA and CSA, which is consistent with the literature that reports SDB to 
be more common in men than in women (Mieno et al., 2018). However, while the 
relationship between gender and CSA was found to be statistically significant, that 
between gender and OSA wasn’t. This finding, especially given that roughly equal 
numbers of males and females were included in both Tables 6 and 7, may perhaps have 
been due to the fact that the females in this study simply had more risk factors for OSA 
than for CSA – such as, for instance, having an average BMI that falls into the category 
of “overweight” according to guidelines from the National Institutes of Health (NIH) 
(Nuttall, 2015). Another explanation for the different results could be that the criteria 
used to establish OSA presence in this study – namely, an AHI≥5 – had led to all 
patients, representing a wide range of disease severity, being included in the data 
analysis. Alternatively, it could be that some aspect of the underlying mechanism of CSA 
pathogenesis is simply more affected by factors unique to gender. 
The results of the analysis of postmenopausal status on CSA risk were interesting 
in that although only 5 out of 40 postmenopausal females had a CAHI≥5 and/or high loop 
gain, of the remaining 35 postmenopausal females, the majority had AF (n=27 or 77.1%). 
Additionally, because five patients were missing information regarding their AF status, 
this percentage may be an underestimation. These results appear contradictory – on one 
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hand, research shows that the presence of AF increases CSA risk in both genders (Sin et 
al., 1999). At the same time, it has been reported that postmenopausal women have a 
higher risk of CSA than premenopausal women due to hormonal differences between the 
two groups (Grayburn et al., 2014). Thus, both AF and postmenopausal status increase 
CSA risk, yet in the study population examined, most postmenopausal women had AF 
but no CSA. These findings may be due to a variety of factors, such as the criteria used to 
classify CSA in this study (CAHI≥5 and/or high loop gain), the accuracy and reliability 
of the WatchPAT testing device in detecting central events, or perhaps the presence of 
other comorbidities whose effects on CSA risk haven’t been examined. An important 
limitation is that females in this study were assumed to have reached menopause by age 
51; this, of course, is not verified. 
 
Treatment: Outcomes and Compliance 
 
 The PAP therapy treatment outcomes over three and six months, as shown in 
Table 10, are generally promising. The results show that the percentages of patients who 
can be considered to have good adherence to therapy – those who use their device at least 
4 hours per night for 70% of nights or more – are relatively high at both the three and six 
month checkpoints (Miech et al., 2019). Additionally, the parameters describing sleep 
pathology – respiratory indices and periodic breathing – were all on a pattern of decline 
at both three and six months. These results and trends demonstrate that, on average, the 




 However, both of the parameters describing the amount of mask leak increased, 
albeit slightly, over the course of three months. Studies have found that a greater amount 
of mask leakage reflects greater non-adherence to therapy (Valentin et al., 2011). 
Furthermore, although the group of patients studied had, on average, relatively high 
adherence to therapy, there was nevertheless a pattern of attrition. Attrition is a common 
issue in treating patients with SDB, with one study reporting that data collected over a 
twenty-year period show consistently low levels of adherence to CPAP (Rotenberg et al., 
2016). The reasons behind this consistent decrease in compliance is perhaps quite 
understandable from the standpoint of the patient who is required to wear a mask while 
sleeping, and may find doing so cumbersome or intolerable. Although the decreases in 
therapy use seen in this study population were relatively minor, the issue of compliance 
to PAP therapy is still an important clinical challenge in the treatment of individuals with 
SDB. As PAP therapy can significantly improve disease prognosis, it is imperative for 
clinicians to continue to encourage therapy compliance and for research to evaluate 
alternative methods that may be effective in improving adherence, such as, for instance, 
behavioral interventions (Weaver, 2019). 
 When considering how treatment efficacy outcomes may have varied by gender, 
no significant differences were found between males and females for the three respiratory 
indices examined, but both genders nevertheless saw improvements from three to six 
months of therapy use. These results are consistent with a previous study which reported 
that both males and females with OSA experienced beneficial changes through usage of 
CPAP (Ye et al., 2009). The interpretation for this finding is that perhaps the mechanism 
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of improvement in disease severity, as accomplished through use of PAP therapy, does 
not depend as heavily on gender as it does on modifiable factors such as compliance. 
 
Treatment: Effects on Cardiac Status 
 
 As previously stated, research into the effects of PAP therapy on AF is limited, 
but of significant clinical importance. The results of Table 12, which compared LVEF 
data from ECG reports with PAP therapy compliance data, preliminarily demonstrate that 
therapy may indeed have a positive impact on AF. Although the sample size is very small 
and the LVEF percentages are solely estimates, the pattern seen in the table suggests that 
patients who had both a high initial compliance at three months and minimal changes in 
compliance at the six month checkpoint were able to have a normal LVEF, reflecting 
improvements in cardiac status and possibly AF as well. Given the bidirectional nature of 
the SDB-AF relationship, it is unsurprising that treating SDB may lead to improvements 
in AF. 
 While Patients 4 and 5 had both been on therapy for a few months when their 
LVEF data were collected, Patient 4 had a 6.5% decrease in compliance while Patient 5 
had only a 0.6% decrease in compliance. Additionally, whereas Patient 4 had an initial 
three-month compliance of 70.1%, Patient 5 had a much higher compliance at three 
months, 93.2%. Taking these differences into consideration, it is possible that the lower 
compliance and attrition seen with Patient 4 may have negatively impacted cardiac 
outcomes; not only did Patient 4 have the lowest initial three-month compliance and 
greatest compliance change from three to six months, but he/she also had the lowest 
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LVEF seen in Table 12 as well. These results highlight the importance and potential 
effects of PAP therapy compliance on cardiac outcomes. Separately, and unsurprisingly, 
none of the patients in Table 12 were recorded as having significant increases in 
compliance from three to six months; most patients experienced decreases in compliance 
during this timeframe. This is consistent with the previous discussion on decreases in 
PAP therapy compliance being frequent amongst SDB patients. However, given that 
there is a possibility that therapy compliance can modulate cardiac outcomes, the 
importance of compliance becomes even greater. 
 
Implications for Screening 
 
Analysis of ESS data generated results that are consistent with what previous 
studies have reported – that although SDB is common in AF patients, the majority of 
these AF patients do not have high ESS scores (Lavergne et al., 2015). That the mean 
ESS for patients with a CAHI≥5 and/or high loop gain was similar to that for patients 
with a CAHI of 0 is perplexing, given that SDB is known to cause excessive daytime 
sleepiness. The reasons for patients with SDB – both OSA and CSA – not reporting high 
levels of subjective sleepiness are unclear; however, this finding has important 
implications for screening cardiology patients for SDB. Knowing that AF patients with 
undiagnosed SDB may report low levels of subjective sleepiness, other methods of 
screening for SDB in this patient population are necessary. 
An important limitation to the ESS findings, however, is that not all patients had 
an ESS value reported on their WatchPAT sleep study report. Additionally, there are also 
 
44 
limitations due to technology – the percentages of deep sleep as recorded with 
WatchPAT are only rough estimates, as there are often inaccuracies in sleep phase 
percentage measurements with home testing devices. 
 
Collaborative Care Model for Sleep Management in Atrial Fibrillation 
 
 As evident from the previous discussion on implications for screening, a new 
collaborative care model for managing SDB in AF patients is needed. Since a substantial 
number of AF patients may present with minimal SDB symptoms – such as low levels of 
subjective sleepiness – it becomes important to shift the focus on screening patients 
solely based on symptoms, as a symptom-based approach may not be as effective in this 
group of individuals. Instead, it may become necessary to screen all AF patients for SDB, 
especially those patients who have a high risk of SDB due to severe AF. In this case, 
home sleep apnea testing using, for instance, the WatchPAT device is less burdensome 
for patients. However, it should be emphasized that home testing tends to underestimate 
disease severity; thus, devices such as WatchPAT should only be used to preliminarily 
screen AF patients for SDB. It may become necessary to follow up on sleep testing using 
in-lab PSG, especially for those patients whose WatchPAT sleep study results are either 
inconclusive or indicative of a severe disease phenotype. 
 Since SDB and AF are conditions known to affect each other in a bidirectional 
relationship, it is necessary for sleep medicine clinicians and cardiologists to collaborate 
with one another in the interest of optimizing patient care. One way that improvements in 
managing SDB in AF patients can likely be achieved is through risk stratifying patients. 
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Given that this study found a significant association between gender and CSA in 
particular, it may be worthwhile to identify those male patients with preexisting AF who 
obtain high CAHI scores from initial home sleep apnea testing. Additionally, since PAP 
therapy treatment may impact cardiac status, it is important for patients who are referred 





Besides the limitations already mentioned, there are a number of other limitations 
in this study. Regarding the data used, some patients had an empty medical history 
section on their WatchPAT sleep study report, which may have led to an underreported 
frequency of AF or other important conditions such as HF. Second, the therapy data 
available were very mixed – not all patients had the same types of data available. For 
instance, some patients had only three-month compliance data, while others had both 
three- and six-month data. In terms of cardiac data, not all patients had LVEF data, and 
the LVEF data that was available was only an estimation – a 55% LVEF was used as a 
threshold and some patients reported a value more than 55%. These factors made direct 
comparisons between patients difficult. Moreover, there were patients with a CAHI≥5 
and/or high loop gain who did not have compliance data; these patients were therefore 
not analyzed because of the inability to see the potential impact of PAP therapy on their 
cardiac status. Perhaps most important, however, is the fact that the improvement in 
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cardiac status cannot necessarily be attributed to the use of PAP therapy – no causality 
can be established. 
 Finally, the study design itself is limited in several aspects, such as the fact that a 
retrospective analysis was conducted and a small patient population was studied. These 
factors make the results more prone to bias and error and also decrease the power of the 
study. Furthermore, the largely unequal numbers of males and females made it difficult to 




This study, though limited by a small sample size, has verified the findings of 
previous studies regarding the association between AF and CSA risk, and has further 
explored how gender may impact the type of sleep apnea seen in an individual. However, 
this study has also examined the specific relationship between postmenopausal status in 
females and risk of CSA, generating mixed results that warrant further investigation into 
how AF and postmenopausal status influence CSA risk in this group of individuals, and 
whether or not other factors are involved in this interplay. Future directions include 
exploring whether or not males with AF present with CSA earlier than females with AF. 
Answers to questions of this nature would ultimately have important implications in 
screening for, diagnosing and treating CSA in the most susceptible group of patients. 
In terms of the effects of PAP therapy, the results from analysis and comparison 
of cardiac and compliance data provided limited, yet promising evidence that therapy 
may be associated with positive changes in cardiac status, and suggested that compliance 
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may prove to play a major role in determining the extent of cardiac improvement. 
However, further research with larger patient samples and more extensive data is needed 
to definitively establish these findings. Future studies should determine the specific types 
of PAP therapy that are most efficacious, as well as the minimum length of time an 
individual is required to be on therapy in order to experience beneficial changes in 
cardiac status. 
In essence, this study has further strengthened the concept of an interrelationship 
between CSA and AF – not only does AF predispose to CSA, but treatment of CSA is 
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